Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3271368 | 0.84 | HRH3 (0.51) | HRH3KCNH2HRH2CACNA1BHRH1 | |
| SCHEMBL3272766 | 0.83 | HRH3 (0.58) | HRH3KCNH2HRH2HRH1ALDH1A1 | |
| SCHEMBL3271377 | 0.82 | HRH3 (0.55) | HRH3KCNH2HRH2HRH1LTA4H | |
| SCHEMBL3271840 | 0.82 | HRH3 (0.57) | HRH3KCNH2HRH2HRH1 | |
| SCHEMBL3272777 | 0.81 | HRH3 (0.64) | HRH3KCNH2ALDH1A1 | |
| SCHEMBL13309599 | 0.81 | HRH3 (0.49) | HRH3KCNH2ALDH1A1 | |
| SCHEMBL3271972 | 0.80 | HRH3 (0.68) | HRH3KCNH2ALDH1A1 | |
| SCHEMBL3273298 | 0.80 | HRH3 (0.52) | HRH3KCNH2LTA4HALDH1A1 | |
| SCHEMBL3276768 | 0.80 | HRH3 (0.54) | HRH3KCNH2HRH2HRH1LTA4H | |
| SCHEMBL3270832 | 0.79 | HRH3 (0.61) | HRH3KCNH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1747210-B1 | 3- OR 4-MONOSUBSTITUTED PHENOL AND THIOPHENOL DERIVATIVES USEFUL AS H3 LIGANDS | WARNER LAMBERT CO (US) | 2010-06-30 | — | — | EP | disclosed |
| US-7456164-B2 | Useful for treatment of H3-related diseases such as neurologic disorders, or inflammatory, respiratory and allergic diseases, disorders and conditions; for example, 4-[4-(1-isopropylpiperidin-4-yloxy)phenyl]tetrahydropyran-4-carbonitrile; well absorbed from gastrointestinal tract, metabolically stable | PFIZER, INC (US) | 2008-11-25 | — | — | US | disclosed |
| US-20050267095-A1 | 3- or 4-monosubstituted phenol and thiophenol derivatives useful as H3 ligands | ZIARCO INC. | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267095-A1 | 3- or 4-monosubstituted phenol and thiophenol derivatives useful as H3 ligands | HRH4, HRH3, TLR4 | HRH3 2/4885KCNH2 3255/4885HRH2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.